Clinical Trials Logo

HER2-positive Gastric Cancer clinical trials

View clinical trials related to HER2-positive Gastric Cancer.

Filter by:

NCT ID: NCT02378389 Recruiting - Clinical trials for HER2 Positive Gastric Cancer

Study Evaluating Pyrotinib/Pyrotinib in Combination With Docetaxel in Patients With HER2+ Advanced Gastric Cancer

Start date: September 2014
Phase: Phase 1
Study type: Interventional

Pyrotinib is an oral tyrosine kinase inhibitor targeting both EGFR and HER-2 receptors. This study is designed to evaluate the safety and tolerability of Pyrotinib or Pyrotinib in combination with Docetaxel in patients with HER2 positive advanced gastric cancer.